Zinc Supplementation and Cardiovascular Risk in HIV
Zinc Supplementation and Cardiovascular Risk in HIV
The purpose of this pilot study is to determine whether zinc supplementation significantly
 affects immune activation in HIV-infected subjects.
Inclusion Criteria:

 -  HIV-1 infection

 -  Age ≥18 years

 -  Zinc level ≤0.75 mg/L

 -  Receiving a stable antiretroviral regimen with no plans to change during study

 -  Documentation of an HIV-1 RNA level of ≤400 copies/mL

 -  No diarrhea or nausea/vomiting for the last month

 Exclusion Criteria:

 -  Pregnancy/lactation

 -  Presence of inflammatory condition

 -  Regular use of agents that may affect inflammation in the last 3 months. The regular
 use of NSAIDS, aspirin, or statins will be allowed as long as dose has been stable for
 the last 3 months and is not expected to change during the study.

 -  Presence of active neoplastic diseases requiring chemotherapy and/or use of
 immunosuppressive drugs

 -  Known cardiovascular disease

 -  Uncontrolled diabetes

 -  Allergy or intolerance to zinc sulfate.

 -  AST and ALT > 2.5 x ULN

 -  Hemoglobin < 9.0 g/dL

 -  GFR <50 mL/min